P2Y receptor subtypes differentially couple to inwardly-rectifying potassium channels

FEBS Letters

Volumn 436, Issue 1, 1998, Pages 104-110

  Mosbacher, J ^a   Maier, R ^a   Fakler, B ^b   Glatz, A ^a   Crespo, J ^a   Bilbe, G ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

G protein; G protein activated Kir; P2Y; Pertussis toxin; Purinoceptor; Xenopus oocyte

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHLORIDE CHANNEL; GUANINE NUCLEOTIDE BINDING PROTEIN; PERTUSSIS TOXIN; POTASSIUM CHANNEL; PURINE P2Y RECEPTOR; RECEPTOR SUBTYPE; SURAMIN; URIDINE DIPHOSPHATE;

ANIMAL CELL; ARTICLE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; XENOPUS;

ADENOSINE TRIPHOSPHATE; ANIMALS; CALCIUM; CHLORIDE CHANNELS; ELECTROPHYSIOLOGY; FEMALE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; OOCYTES; PERTUSSIS TOXIN; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, PURINERGIC P2; RECOMBINANT PROTEINS; SURAMIN; URIDINE TRIPHOSPHATE; VIRULENCE FACTORS, BORDETELLA; XENOPUS LAEVIS;

EID: 0032566744     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(98)01066-7     Document Type: Article

References (29)

1. Burnstock G. Drug Dev. Res. 39:1996;204-242.
2. Barnard E.A., Simon J., Webb T.E. Mol. Neurobiol. 15:1997;103-129.
3. Fredholm B.B., Abbracchio M.P., Burnstock G., Dubyak G.R., Harden T.K., Jacobson K.A., Schwabe U., Williams M. Trends Pharmacol. Sci. 18:1997;79-82.
4. Harden T.K., Boyer J.L., Nicholas R.A. Annu. Rev. Pharmacol. Toxicol. 35:1995;541-579.
5. Gandia L., Garcia A.G., Morad M. J. Physiol. (Lond.). 470:1993;55-72.
6. Ikeuchi Y., Nishizaki T., Mori M., Okada Y. Eur. J. Pharmacol. 304:1996;191-199.
7. Lim W., Kim S.J., Yan H.D., Kim J. Pflüg. Arch. 435:1997;34-42.
8. Motte S., Pirotton S., Boeynaems J.M. Circ. Res. 72:1993;504-510.
9. Schulze-Lohoff E., Bitzer M., Ogilvie A., Sterzel R.B. Renal Physiol. Biochem. 18:1995;219-230.
10. Webb T.E., Feolde E., Vigne P., Neary J.T., Runberg A., Frelin C., Barnard E.A. Br. J. Pharmacol. 119:1996;1385-1392.
11. Boyer J.L., Lazarowski E.R., Chen X.H., Harden T.K. J. Pharmacol. Exp. Ther. 267:1993;1140-1146.
12. Matsuura H., Sakaguchi M., Tsuruhara Y., Ehara T. J. Physiol. (Lond.). 490:1996;659-671.
13. Friel D.D., Bean B.P. Pflüg. Arch. 415:1990;651-657.
14. Clapham D.E., Neer E.J. Annu. Rev. Pharmacol. Toxicol. 37:1997;167-203.
15. Communi D., Motte S., Boeynaems J.M., Pirotton S. Eur. J. Pharmacol. 317:1996;383-389.
16. Communi D., Govaerts C., Parmentier M., Boeynaems J.M. J. Biol. Chem. 272:1997;31969-31973.
17. Parr C.E., Sullivan D.M., Paradiso A.M., Lazarowski E.R., Burch L.H., Olsen J.C., Erb L., Weisman G.A., Boucher R.C., Turner J.T. Proc. Natl. Acad. Sci. USA. 91:1994;3275-3279.
18. Filippov A.K., Webb T.E., Barnard E.A., Brown D.A. Br. J. Pharmacol. 121:1997;849-851.
19. King B.F., Wang S., Burnstock G. J. Physiol. (Lond.). 494:1996;17-28.
20. Lustig K.D., Shiau A.K., Brake A.J., Julius D. Proc. Natl. Acad. Sci. USA. 90:1993;5113-5117.
21. Maier R., Glatz A., Mosbacher J., Bilbe G. Biochem. Biophys. Res. Commun. 240:1997;298-302.
22. Gudermann T., Schoneberg T., Schultz G. Annu. Rev. Neurosci. 20:1997;399-427.
23. Sharon D., Vorobiov D., Dascal N. J. Gen. Physiol. 109:1997;477-490.
24. Communi D., Raspe E., Pirotton S., Boeynaems J.M. Circ. Res. 76:1995;191-198.
25. Saugstad J.A., Segerson T.P., Westbrook G.L. J. Neurosci. 16:1996;5979-5985.
26. Milligan G. Trends Pharmacol. Sci. 14:1993;239-244.
27. Vallar L., Muca C., Magni M., Albert P., Bunzow J., Meldolesi J., Civelli O. J. Biol. Chem. 265:1990;10320-10326.
28. Raymond J.R., Albers F.J., Middleton J.P., Lefkowitz R.J., Caron M.G., Obeid L.M., Dennis V.W. J. Biol. Chem. 266:1991;372-379.
29. Hung D.T., Wong Y.H., Vu T.K., Coughlin S.R. J. Biol. Chem. 267:1992;20831-20834.